Zogenix reports Q2 EPS (93c), consensus (89c)
Reports Q2 revenue $7.13M, consensus $3.48M. The company said,"We remain on target to announce Study 1 top-line results from our ZX008 Phase 3 program in Dravet syndrome late in the third quarter of this year. The completion of Study 1 will be a significant milestone for our company, as it will represent the culmination of over two years of effort at Zogenix. Importantly, these will be the first results from one of our placebo-controlled, clinical trial evaluating the potential of low-dose fenfluramine as a safe and effective treatment for Dravet syndrome. In addition, our second planned pivotal Phase 3 data readout for Dravet syndrome, Study 1504, has enrolled approximately two-thirds of the targeted number of subjects. We are focused on completing enrollment in Study 1504 by the end of the current quarter."